148 related articles for article (PubMed ID: 23838926)
21. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.
Van Cutsem E; Rivera F; Berry S; Kretzschmar A; Michael M; DiBartolomeo M; Mazier MA; Canon JL; Georgoulias V; Peeters M; Bridgewater J; Cunningham D;
Ann Oncol; 2009 Nov; 20(11):1842-7. PubMed ID: 19406901
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer.
Inanç M; Er O; Karaca H; Berk V; Ozkan M; Saraymen R; Elmalı F
Med Oncol; 2012 Dec; 29(5):3119-24. PubMed ID: 22580817
[TBL] [Abstract][Full Text] [Related]
23. Oxaliplapin and capecitabine (XELOX) based chemotherapy in the treatment of metastatic colorectal cancer: the right choice in elderly patients.
Berretta M; Aprile G; Nasti G; Urbani M; Bearz A; Lutrino S; Foltran L; Ferrari L; Talamini R; Fiorica F; Lleshi A; Canzonieri V; Lestuzzi C; Borsatti E; Fisichella R; Tirelli U
Anticancer Agents Med Chem; 2013 Nov; 13(9):1344-53. PubMed ID: 24102280
[TBL] [Abstract][Full Text] [Related]
24. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
25. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT].
Clarke S; Burge M; Cordwell C; Gibbs P; Reece W; Tebbutt N
BMC Cancer; 2013 Mar; 13():120. PubMed ID: 23497305
[TBL] [Abstract][Full Text] [Related]
26. MGMT -535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy.
Park JH; Kim NS; Park JY; Chae YS; Kim JG; Sohn SK; Moon JH; Kang BW; Ryoo HM; Bae SH; Choi GS; Jun SH
J Cancer Res Clin Oncol; 2010 Aug; 136(8):1135-42. PubMed ID: 20091185
[TBL] [Abstract][Full Text] [Related]
27. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas.
Acikalin MF; Oner U; Topçu I; Yaşar B; Kiper H; Colak E
Dig Liver Dis; 2005 Mar; 37(3):162-9. PubMed ID: 15888280
[TBL] [Abstract][Full Text] [Related]
28. A prospective study of XELOX plus bevacizumab as first-line therapy in Japanese patients with metastatic colorectal cancer (KSCC 0902).
Ogata Y; Shimokawa M; Tanaka T; Emi Y; Oki E; Saeki H; Sadanaga N; Kusumoto T; Touyama T; Kimura M; Baba H; Akagi Y; Shirouzu K; Maehara Y;
Int J Clin Oncol; 2016 Apr; 21(2):335-343. PubMed ID: 26338269
[TBL] [Abstract][Full Text] [Related]
29. Out-of-pocket payment and cost-effectiveness of XELOX and XELOX plus bevacizumab therapy: from the perspective of metastatic colorectal cancer patients in Japan.
Shiroiwa T; Fukuda T; Tsutani K
Int J Clin Oncol; 2010 Jun; 15(3):256-62. PubMed ID: 20198398
[TBL] [Abstract][Full Text] [Related]
30. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy.
Alonso-Espinaco V; Cuatrecasas M; Alonso V; Escudero P; Marmol M; Horndler C; Ortego J; Gallego R; Codony-Servat J; Garcia-Albeniz X; Jares P; Castells A; Lozano JJ; Rosell R; Maurel J
Eur J Cancer; 2014 Jul; 50(11):1973-81. PubMed ID: 24833563
[TBL] [Abstract][Full Text] [Related]
31. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers of anti-angiogenic therapy in metastatic colorectal cancer (mCRC): original data and review of the literature.
Pohl M; Werner N; Munding J; Tannapfel A; Graeven U; Nickenig G; Schmiegel W; Reinacher-Schick A
Z Gastroenterol; 2011 Oct; 49(10):1398-406. PubMed ID: 21964893
[TBL] [Abstract][Full Text] [Related]
33. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer.
Jubb AM; Hurwitz HI; Bai W; Holmgren EB; Tobin P; Guerrero AS; Kabbinavar F; Holden SN; Novotny WF; Frantz GD; Hillan KJ; Koeppen H
J Clin Oncol; 2006 Jan; 24(2):217-27. PubMed ID: 16365183
[TBL] [Abstract][Full Text] [Related]
34. Thymidine phosphorylase expression is associated with response to capecitabine plus irinotecan in patients with metastatic colorectal cancer.
Meropol NJ; Gold PJ; Diasio RB; Andria M; Dhami M; Godfrey T; Kovatich AJ; Lund KA; Mitchell E; Schwarting R
J Clin Oncol; 2006 Sep; 24(25):4069-77. PubMed ID: 16943524
[TBL] [Abstract][Full Text] [Related]
35. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Lichinitser M; Yang TS; Rivera F; Couture F; Sirzén F; Saltz L
J Clin Oncol; 2008 Apr; 26(12):2006-12. PubMed ID: 18421053
[TBL] [Abstract][Full Text] [Related]
36. Capecitabine-related increased mean corpuscular volume of red blood cell may be a predictive marker of treatment response and survival in patients with metastatic colorectal cancer.
Cokmert S; Demir L; Can A; Akyol M; Vedat Bayoglu I; Dirican A; Kucukzeybek Y; Erten C; Oktay Tarhan M
J BUON; 2014; 19(1):75-82. PubMed ID: 24659646
[TBL] [Abstract][Full Text] [Related]
37. Capecitabine and oxaliplatin (XELOX) as first-line treatment for patients with metastatic colorectal cancer.
Karacetin D; Yalcin B; Okten B; Ozturk S; Maral O; Incekara O
J BUON; 2009; 14(4):605-8. PubMed ID: 20148449
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Baraniskin A; Munding J; Schulmann K; Meier D; Porschen R; Arkenau HT; Graeven U; Schmiegel W; Tannapfel A; Reinacher-Schick A
Clin Colorectal Cancer; 2011 Mar; 10(1):24-9. PubMed ID: 21609932
[TBL] [Abstract][Full Text] [Related]
39. Comparison of first-line bevacizumab in combination with mFOLFOX6 or XELOX in metastatic colorectal cancer.
Vedat Bayoglu I; Yildiz I; Varol U; Cokmert S; Kucukzeybek Y; Alacacioglu A; Demir L; Dirican A; Akyol M; Yildiz Y; Oktay Tarhan M
J BUON; 2015; 20(2):460-7. PubMed ID: 26011336
[TBL] [Abstract][Full Text] [Related]
40. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: phase III 'Stop and Go' study results--a Turkish Oncology Group Trial.
Yalcin S; Uslu R; Dane F; Yilmaz U; Zengin N; Buyukunal E; Buyukberber S; Camci C; Sencan O; Kilickap S; Ozdener F; Cevik D
Oncology; 2013; 85(6):328-35. PubMed ID: 24247559
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]